tiprankstipranks
Trending News
More News >
Kaken Pharmaceutical Co (JP:4521)
:4521
Japanese Market

Kaken Pharmaceutical Co (4521) Income Statement

Compare
0 Followers

Kaken Pharmaceutical Co Income Statement

Last quarter (Q1 2026), Kaken Pharmaceutical Co's total revenue was ¥18.87B, an increase of 3.36% from the same quarter last year. In Q1, Kaken Pharmaceutical Co's net income was ¥271.00M. See Kaken Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
¥ 94.03B¥ 72.04B¥ 72.98B¥ 76.03B¥ 74.98B
Gross Profit
¥ 58.26B¥ 38.54B¥ 39.56B¥ 41.58B¥ 40.91B
Operating Expenses
¥ 37.23B¥ 29.03B¥ 31.55B¥ 24.51B¥ 23.11B
Depreciation and Amortization
¥ 2.55B¥ 2.75B¥ 2.57B¥ 2.48B¥ 2.32B
EBITDA
¥ 22.02B¥ 12.57B¥ 9.40B¥ 16.38B¥ 20.99B
Operating Income
¥ 21.04B¥ 9.51B¥ 8.00B¥ 17.06B¥ 17.79B
Other Income/Expenses
¥ -1.60B¥ 283.00M¥ -1.18B¥ -3.18B¥ 869.00M
Pretax Income
¥ 19.43B¥ 9.80B¥ 6.82B¥ 13.88B¥ 18.66B
Net Income
¥ 13.95B¥ 8.03B¥ 5.44B¥ 9.55B¥ 13.40B
Per Share Metrics
Basic EPS
¥ 365.42¥ 212.66¥ 144.79¥ 251.44¥ 347.37
Diluted EPS
¥ 365.42¥ 212.66¥ 144.79¥ 251.44¥ 347.37
Weighted Average Shares Outstanding
38.16M 37.74M 37.57M 37.98M 38.59M
Weighted Average Shares Outstanding (Diluted)
38.16M 37.74M 37.57M 37.98M 38.59M
Currency in JPY

Kaken Pharmaceutical Co Earnings and Revenue History